UPFRONT BRIEFING
J&J turned Sunday's FT report into a signed $2.2B-upfront buyout of Ollin, then handed most of the Phase 3 bill to Blackstone, which is fast becoming big pharma's favourite co-signer. CG Oncology, meanwhile, posted the kind of Phase 3 bladder data that makes a 30-40% bar look quaint.
Lilly kept the checkbook open with a $1.5B Calytrix buyout and an up-to-$5.9B Stipple research pact, while Summit learned the FDA still wants survival, not just progression-free months. Jefferies London runs through Thursday, and the Senate HELP committee votes on FDA nominee Heidi Overton tomorrow.
TAPE ACTION

Biotech lagged a weak tape: XBI (3.1%), NBI (2.0%) and BBC (4.0%) against XLV (0.5%) and the S&P 500 (1.9%). Single names: CG Oncology closed +14.0% on its 08:00 ET Phase 3 bladder readout, Summit (16.5%) on Sunday's ivonescimab CRL, and Helus (13.5%) after Phase 3 depression data carried three serious adverse events.
Chips led a third straight S&P loss into Nvidia's results Tuesday after the close: Nvidia (4.1%), AMD (5.6%), Micron (7.6%) and Intel (7.0%), alongside a new Commerce rule restricting remote access to advanced chips. November Empire State manufacturing fell to 7.8 vs ~16.7 expected; the 10-year eased 2bp to 5.13% and Brent fell 3.5% to $92.44. Nasdaq 100 (2.7%), Russell 2000 (1.7%), Dow (1.4%).
THE BIG 3
1️⃣ — CG Oncology's cretostimogene cuts bladder cancer recurrence 68% in Phase 3
PIVOT-006 (n=367, ~90 US/Canada sites) randomised intermediate-risk and high-grade Ta NMIBC patients to adjuvant cretostimogene or surveillance after resection: recurrence-free survival HR 0.32 (95% CI 0.23-0.45, p<0.0001) at 17 months' median follow-up, with no Grade 3+ treatment-related AEs or discontinuations. Full data at SUO on 2 December; CGON closed +14.0% Monday.
Why it matters: The Street had framed a 30-40% risk reduction as a win; 68% clears that by a distance, and with surveillance as the comparator there is no active standard of care for payers to anchor against. CG now has two shots on goal: the broadened BCG-unresponsive BLA by end-March 2027 and a second BLA in intermediate-risk disease in Q2 2027. RBC's Leonid Timashev puts US peak sales at up to $3.2B by 2035, and TD Cowen sees cretostimogene as likely the only agent available in both settings, a direct challenge to J&J's TAR-200 and enGene's detalimogene. No RFS rates are out yet, and the first filing has slipped more than once, so the SUO podium on 2 December carries weight.
Source: STAT
More: Fierce Biotech; BioPharma Dive
2️⃣ — J&J signs $2.2B-upfront Ollin buyout as Blackstone funds Phase 3
J&J signed a definitive deal for Ollin Biosciences (ARCH, TCGX, Mubadala-backed): $2.2B upfront plus up to ~$1.125B in regulatory and commercial milestones (~$3.3B), closing before year-end. Blackstone will pay J&J $750M over several years to fully fund OLN324's Phase 3 programme in wet AMD and DME, contingent on close.
Why it matters: J&J is paying $2.2B upfront plus up to about $1.125B in milestones, then handing most of the Phase 3 bill to Blackstone: $750M over several years, recouped through milestones and single-digit royalties if OLN324 reaches market. That turns a late-stage eye bet into a capped-cost option, the same co-funding template Blackstone ran with Pfizer on berobenatide last week. OLN324, an Innovent-originated VEGF/Ang2 bispecific, is aimed squarely at Roche's Vabysmo, with four Phase 3s against Lucentis or Eylea in wet AMD and DME. RBC's Trung Huynh calls the price high against peers and questions how differentiated the drug is in a crowded class. The China origin brings COINS overhang; close is expected before year-end.
Source: Fierce Biotech
More: BioPharma Dive; J&J release
3️⃣ — Lilly signs up to $5.9B oncology research pact with Stipple Bio
Lilly takes exclusive worldwide rights to products built on binders from Stipple's Pointillist platform, which maps tumour-specific cell-surface epitopes. Stipple gets an undisclosed upfront, a Lilly equity investment, up to $5.9B in research, development and commercial milestones, and tiered royalties (announced Monday 16:00 ET).
Why it matters: The headline is almost all contingent: upfront and equity stake undisclosed, no named targets, and Stipple's lead ADC, STP-100, only reaches Phase 1 in early 2027. What Lilly is buying is target discovery, tumour-restricted epitopes that let it attach its own payloads and modalities without the on-target, off-tumour toxicity that caps many ADCs. The same day Lilly paid up to $1.5B for Calytrix, a CALR-mutant MPN biparatopic antibody play, its 15th acquisition of 2026 and more than $30B spent this year, per BioPharma Dive. For private oncology platforms, Lilly is now the marginal bidder; for Stipple's peers, milestone-heavy structures remain the price of entry.
Source: Endpoints
More: Stipple Bio release
EVERYTHING ELSE THAT BROKE
Summit closed down 16.5% and Akeso fell 22% in Hong Kong as Monday's trading caught up with Sunday's ivonescimab CRL, after the FDA ruled that progression-free survival without a survival benefit at the primary analysis was not enough. — BioPharma Dive
FDA approved Roche's Wilserdly (giredestrant) plus everolimus in ER+/HER2- ESR1-mutated advanced breast cancer on evERA (PFS HR 0.38), with the adjuvant lidERA decision due 30 November (after the close). — STAT
Roche's Gazyva won its first FDA nod in primary membranous nephropathy, a third immune-mediated indication. — Fierce Pharma
AstraZeneca's Klygefa (gefurulimab) won FDA approval as a once-weekly self-administered C5 option in generalized myasthenia gravis, extending the Soliris/Ultomiris franchise. — Fierce Pharma
Helus reported Phase 3 efficacy for psilocin-based HLP003 in depression, but three serious adverse events clouded the win; shares closed down 13.5%. — STAT
Aclaris dropped TSLP antibody bosakitug after it missed the primary endpoint of a Phase 2 atopic dermatitis study, the latest setback for anti-TSLP drugs in eczema; shares closed down 8.0%. — Fierce Biotech
Chinese authorities fired two researchers over a child's death in a gene-editing study, according to state media. — Fierce Biotech
Leqembi's five-year Clarity AD extension data at CTAD showed a 36% lower risk of progression to the next disease stage versus ADNI. — PR
Apotex launched the first U.S. generic of Inlyta (axitinib), opening pricing pressure in renal cell carcinoma. — PR
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
J&J / Ollin Biosciences - definitive acquisition, $2.2B upfront + up to ~$1.125B milestones; Blackstone funds $750M of OLN324 Phase 3 for milestones and single-digit royalties; close by YE26 (see The Big 3). — Fierce Biotech
Lilly / Stipple Bio - oncology research collaboration and licence, undisclosed upfront + equity, up to $5.9B milestones, tiered royalties (see The Big 3). — Endpoints
Lilly / Calytrix Bio - acquisition up to $1.5B (upfront undisclosed), biparatopic antibody for CALR-mutant myelofibrosis and essential thrombocythemia; Lilly's 15th buyout of 2026. — Fierce Biotech
Novartis / OBI Pharma - exclusive worldwide licence to OBI's Obrion ADC linker/conjugation platform for select Novartis payload classes, $30M upfront, total potential value >$2B plus tiered royalties. — PR
Sanofi / Seawolf Therapeutics - multi-target research collaboration and exclusive licence for DNA-LNP therapies starting in bleeding disorders, up to $1.2B milestones plus tiered royalties. — BioPharma Dive
Biogen / TrimTech - neurodegeneration protein-degrader collaboration worth up to $411M. — Fierce Biotech
VC / PRIVATE FINANCINGS
Seawolf Therapeutics emerged from stealth with $100M across seed and Series A, Versant (founder, seed lead) joined by MPM BioImpact, Alexandria, Eli Lilly and Novartis Venture Fund; TRIDENT redosable DNA-LNP platform, lead programme in metabolic disease. — Fierce Biotech
IPO / FOLLOW-ON
Leo Pharma's IPO plans have stalled on market volatility, per Bloomberg. — Fierce Pharma
ACADEMIC CORNER
No relevant academic updates since yesterday's edition.
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
Blackstone is now paying for other people's Phase 3s. Worth asking nicely.
— The BioBucks Team
